Andes Biotechnologies Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Out of Business

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Out of Business

Andes Biotechnologies General Information

Description

Developer of novel therapeutics intended to create a new class of drugs for the treatment of cancer. The company's therapeutics use antisense technologies to target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis, thereby enabling physicians to selectively destroy cancer cells without affecting normal cells.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Parque Tecnológico Zañartu
  • Av. Zañartu, Ñuñoa
  • Santiago, 1482
  • Chile
+56
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Parque Tecnológico Zañartu
  • Av. Zañartu, Ñuñoa
  • Santiago, 1482
  • Chile
+56

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Andes Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Out of Business 20-Dec-2020 Completed Out of Business
6. Later Stage VC 01-Jun-2018 Completed Generating Revenue
5. Later Stage VC (Series B) 15-Apr-2015 Completed Generating Revenue
4. Later Stage VC 10-Mar-2014 Completed Generating Revenue
3. Early Stage VC 10-May-2012 Completed Generating Revenue
2. Early Stage VC (Series A) 19-May-2011 $4M $4M Completed Generating Revenue
1. Grant 11-Jan-2011 Completed Startup
To view Andes Biotechnologies’s complete valuation and funding history, request access »

Andes Biotechnologies Patents

Andes Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2017508467-A Pharmaceutical composition comprising rna for treating cancer and use thereof Inactive 14-Mar-2014
CA-2939860-A1 Pharmaceutical compositions comprising rna and use for treating cancer Inactive 14-Mar-2014
EP-3116513-A2 Pharmaceutical compositions comprising rna and use for treating cancer Inactive 14-Mar-2014
EP-3116513-A4 Pharmaceutical compositions comprising rna and use for treating cancer Inactive 14-Mar-2014
US-20170183650-A1 Pharmaceutical compositions comprising rna and use for treating cancer Inactive 14-Mar-2014 C12N15/113
To view Andes Biotechnologies’s complete patent history, request access »

Andes Biotechnologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Andes Biotechnologies FAQs

  • When was Andes Biotechnologies founded?

    Andes Biotechnologies was founded in 2008.

  • Where is Andes Biotechnologies headquartered?

    Andes Biotechnologies is headquartered in Santiago, Chile.

  • What is the size of Andes Biotechnologies?

    Andes Biotechnologies has 3 total employees.

  • What industry is Andes Biotechnologies in?

    Andes Biotechnologies’s primary industry is Drug Discovery.

  • Is Andes Biotechnologies a private or public company?

    Andes Biotechnologies is a Private company.

  • What is Andes Biotechnologies’s current revenue?

    The current revenue for Andes Biotechnologies is .

  • How much funding has Andes Biotechnologies raised over time?

    Andes Biotechnologies has raised $28M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process